影像组学联合多组学在肝细胞癌的研究进展

doi:10.3969/j.issn.1006-7795.2025.05.025

摘要/Abstract

摘要： 原发性肝癌是目前全球第六大常见恶性肿瘤，肝细胞癌（hepatocellular carcinoma, HCC）占其中的75%~85%。HCC发病率高、异质性强且预后不良，因此对高危人群的早期监测与精细评估尤为重要。近年来，影像组学作为一种非侵入性手段，在HCC的诊断、病理表征、治疗方式的选择和疗效评估中得到了广泛应用。此外，影像组学结合下一代测序技术等多组学方法，为HCC的研究提供了新的思路。本文综述了影像组学联合多组学在HCC领域中的研究进展，以期为HCC的诊疗提供新的视角。

关键词: 肝细胞癌, 影像组学, 多组学, 影像基因组学, 影像免疫组学, 深度学习, 个性化医疗

Abstract: Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor in the world, accounting for 75%-85%. Due to the high incidence, strong heterogeneity and poor prognosis of HCC, early monitoring and fine assessment of high-risk populations are particularly important. In recent years, as a non-invasive method, radiomics has been widely used in the diagnosis, pathological characterization, selection of treatment methods and evaluation of curative effect of HCC. In addition, radiomics combined with next-generation sequencing technology and other multi-omics methods provide new ideas for HCC research. This paper reviews the research progress of radiomics combined with multi-omics in the field of HCC, in order to provide a new perspective for the diagnosis and treatment of HCC.

Key words: hepatocellular carcinoma (HCC), radiomics, multi-omics, radiogenomics, radioimmunomics, deep learning, personalized medicine

中图分类号:

R445

刘彦怡, 张岩岩, 李宏军. 影像组学联合多组学在肝细胞癌的研究进展[J]. 首都医科大学学报, 2025, 46(5): 934-939.

Liu Yanyi, Zhang Yanyan, Li Hongjun. Research advances in radiomics combined with multi-omics in hepatocellular carcinoma[J]. Journal of Capital Medical University, 2025, 46(5): 934-939.

参考文献

［1］ Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA: a cancer journal for clinicians, 2021, 71(3): 209-49. DOI:10.3322/caac.21660
［2］ Heimbach J K, Kulik L M, Finn R S, et al. AASLD guidelines for the treatment of hepatocellular carcinoma［J］. Hepatology, 2018, 67(1): 358-380.
［3］ Liu X Y, Elbanan M G, Luna A, et al. Radiomics in abdominopelvic solid-organ oncologic imaging: current status［J］. AJR Am J Roentgenol, 2022, 219(6): 985-995.
［4］ Liu X Y, Khalvati F, Namdar K, et al. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning?［J］. Eur Radiol, 2021, 31(1): 244-255.
［5］ Mao Y F, Wang J C, Zhu Y, et al. Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma［J］. Hepatobiliary Surg Nutr, 2022, 11(1): 13-24.
［6］ Wu M H, Tan H N, Gao F, et al. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature［J］. Eur Radiol, 2019, 29(6): 2802-2811.
［7］ Xu X, Zhang H L, Liu Q P, et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma［J］. J Hepatol, 2019, 70(6): 1133-1144.
［8］ Feng S T, Jia Y M, Liao B, et al. Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI［J］. Eur Radiol, 2019, 29(9): 4648-4659.
［9］ Chen M Y, Cao J S, Hu J H, et al. Clinical-radiomic analysis for pretreatment prediction of objective response to first transarterial chemoembolization in hepatocellular carcinoma［J］. Liver Cancer, 2021, 10(1): 38-51.
［10］ Kong C L, Zhao Z W, Chen W Y, et al. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE［J］. Eur Radiol, 2021, 31(10): 7500-7511.
［11］ Zheng B H, Liu L Z, Zhang Z Z, et al. Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients［J］. BMC Cancer, 2018, 18(1): 1148.
［12］ Segal E, Sirlin C B, Ooi C, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging［J］. Nat Biotechnol, 2007, 25(6): 675-680.
［13］ Peng J, Lu F Y, Huang J H, et al. Development and validation of a pyradiomics signature to predict initial treatment response and prognosis during transarterial chemoembolization in hepatocellular carcinoma［J］. Front Oncol, 2022, 12: 853254.
［14］ Feng Z C, Li H L, Liu Q Y, et al. CT radiomics to predict macrotrabecular-massive subtype and immune status in hepatocellular carcinoma［J］. Radiology, 2023, 307(1): e221291.
［15］ Liao H T, Jiang H Y, Chen Y T, et al. Predicting genomic alterations of phosphatidylinositol-3 kinase signaling in hepatocellular carcinoma: a radiogenomics study based on next-generation sequencing and contrast-enhanced CT［J］. Ann Surg Oncol, 2022, 29(7): 4552-4564.
［16］ Wang Y Q, Gao B, Xia C H, et al. Development of a novel tumor microenvironment-related radiogenomics model for prognosis prediction in hepatocellular carcinoma［J］. Quant Imaging Med Surg, 2023, 13(9): 5803-5814.
［17］ Xia W, Chen Y, Zhang R, et al. Radiogenomics of hepatocellular carcinoma: multiregion analysis-based identification of prognostic imaging biomarkers by integrating gene data-a preliminary study［J］. Phys Med Biol, 2018, 63(3): 035044.
［18］ Khalili N, Kazerooni A F, Familiar A, et al. Radiomics for characterization of the glioma immune microenvironment［J］. NPJ Precis Oncol, 2023, 7(1): 59.
［19］ Liu Q Y, Zhu W W, Song F L, et al. Radio-immunomics in hepatocellular carcinoma: unraveling the tumor immune microenvironment［J］. Meta-Radiology, 2024, 2(3): 100098.
［20］ Cariani E, Pilli M, Zerbini A, et al. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma［J］. PLoS One, 2012, 7(3): e32493.
［21］ Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies［J］. Mol Cancer, 2017, 16(1): 149.
［22］ Sun R, Limkin E J, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study［J］. Lancet Oncol, 2018, 19(9): 1180-1191.
［23］ Palucka A K, Coussens L M. The basis of oncoimmunology［J］. Cell, 2016, 164(6): 1233-1247.
［24］ Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘immunoscore’ in the classification of malignant tumours［J］. J Pathol, 2014, 232(2): 199-209.
［25］ Bruni D, Angell H K, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy［J］. Nat Rev Cancer, 2020, 20(11): 662-680.
［26］ Gabrielson A, Wu Y N, Wang H K, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC［J］. Cancer Immunol Res, 2016, 4(5): 419-430.
［27］ Hectors S J, Wagner M, Bane O, et al. Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging［J］. Sci Rep, 2017, 7(1): 2452.
［28］ Chen S L, Feng S T, Wei J W, et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging［J］. Eur Radiol, 2019, 29(8): 4177-4187.
［29］ Liao H T, Zhang Z, Chen J, et al. Preoperative radiomic approach to evaluate tumor-infiltrating CD8+ T cells in hepatocellular carcinoma patients using contrast-enhanced computed tomography［J］. Ann Surg Oncol, 2019, 26(13): 4537-4547.
［30］ Sangro B, Chan S L, Meyer T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma［J］. J Hepatol, 2020, 72(2): 320-341.
［31］ Hectors S J, Lewis S, Besa C, et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma［J］. Eur Radiol, 2020, 30(7): 3759-3769.
［32］ Gong X Q, Liu N, Tao Y Y, et al. Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma［J］. Sci Rep, 2023, 13(1): 7710.
［33］ Montalbano M, Rastellini C, McGuire J T, et al. Role of glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma［J］. Cell Oncol, 2018, 41(2): 169-184.
［34］ Chong H H, Gong Y D, Zhang Y F, et al. Radiomics on gadoxetate disodium-enhanced MRI: non-invasively identifying glypican 3-positive hepatocellular carcinoma and postoperative recurrence［J］. Acad Radiol, 2023, 30(1): 49-63.
［35］ Liu P J, Li W Q, Qiu G B, et al. Multiparametric MRI combined with clinical factors to predict glypican-3 expression of hepatocellular carcinoma［J］. Front Oncol, 2023, 13: 1142916.
［36］ Li Z J, Wang Y Y, Yu J H, et al. Deep learning based radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma［J］. Sci Rep, 2017, 7(1): 5467.
［37］ Gul S, Khan M S, Bibi A, et al. Deep learning techniques for liver and liver tumor segmentation: a review［J］. Comput Biol Med, 2022, 147: 105620.
［38］ McBee M P, Awan O A, Colucci A T, et al. Deep learning in radiology［J］. Acad Radiol, 2018, 25(11): 1472-1480.
［39］ Zheng X Y, Yao Z, Huang Y N, et al. Deep learning radiomics can predict axillary lymph node status in early-stage breast cancer［J］. Nat Commun, 2020, 11(1): 1236.
［40］ Wang K, Lu X, Zhou H, et al. Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study［J］. Gut, 2019, 68(4): 729-741.
［41］ Chen Y Y, Chen J, Zhang Y, et al. Preoperative prediction of cytokeratin 19 expression for hepatocellular carcinoma with deep learning radiomics based on gadoxetic acid-enhanced magnetic resonance imaging［J］. J Hepatocell Carcinoma, 2021, 8: 795-808.
［42］ He T C, Fong J N, Moore L W, et al. An imageomics and multi-network based deep learning model for risk assessment of liver transplantation for hepatocellular cancer［J］. Comput Med Imaging Graph, 2021, 89: 101894.
［43］ Ding Y, Ruan S J, Wang Y B Z, et al. Novel deep learning radiomics model for preoperative evaluation of hepatocellular carcinoma differentiation based on computed tomography data［J］. Clin Transl Med, 2021, 11(11): e570.
［44］ Gao W Y, Wang W T, Song D J, et al. A predictive model integrating deep and radiomics features based on gadobenate dimeglumine-enhanced MRI for postoperative early recurrence of hepatocellular carcinoma［J］. Radiol Med, 2022, 127(3): 259-271.
［45］ Peng J, Huang J H, Huang G J, et al. Predicting the initial treatment response to transarterial chemoembolization in intermediate-stage hepatocellular carcinoma by the integration of radiomics and deep learning［J］. Front Oncol, 2021, 11: 730282.
［46］ Guo L X, Hao X, Chen L, et al. Early warning of hepatocellular carcinoma in cirrhotic patients by three-phase CT-based deep learning radiomics model: a retrospective, multicentre, cohort study［J］. EClinicalMedicine, 2024, 74: 102718.
［47］ Pinker K, Chin J, Melsaether A N, et al. Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment［J］. Radiology, 2018, 287(3): 732-747.
［48］ Huang E P, O'Connor J P B, McShane L M, et al. Criteria for the translation of radiomics into clinically useful tests［J］. Nat Rev Clin Oncol, 2023, 20(2): 69-82.
［49］ Liu Z Q, Duan T, Zhang Y Y, et al. Radiogenomics: a key component of precision cancer medicine［J］. Br J Cancer, 2023, 129(5): 741-753.
［50］ Avanzo M, Wei L S, Stancanello J, et al. Machine and deep learning methods for radiomics［J］. Med Phys, 2020, 47(5): e185-e202.
［51］ Li J A, Tian J Y, Liu Y C, et al. Personalized analysis of human cancer multi-omics for precision oncology［J］. Comput Struct Biotechnol J, 2024, 23: 2049-2056.

[1]	王永杰, 崔利宾, 袁鑫, 路茜, 陈学明, 刘亮. 人工智能辅助诊断骨质疏松性椎体压缩骨折的效能分析[J]. 首都医科大学学报, 2025, 46(5): 777-783.
[2]	王拥军, 刘涛, 刘子阳, 熊云云, 荆京, 谢雪微, 李子孝. 人工智能在脑血管病领域中的应用[J]. 首都医科大学学报, 2025, 46(2): 177-183.
[3]	屈俊达, 杨敏福, 李春林, 孙立伟, 高赫, 张旭. 心外膜脂肪影像分割量化方法及其临床应用的研究进展[J]. 首都医科大学学报, 2025, 46(1): 99-105.
[4]	裴友娟, 阮祥燕, 鞠蕊, 王月姣, 蒋玲玲, 马郡. 人工智能在生殖内分泌领域中的应用[J]. 首都医科大学学报, 2024, 45(4): 566-572.
[5]	万妍, 刘芳, 郭闪, 吴剑. 非肝硬化乙型肝炎病毒相关肝细胞癌的转录组测序及其对患者生存的影响[J]. 首都医科大学学报, 2023, 44(5): 811-820.